1. Search Result
Search Result
Results for "

angioedema

" in MedChemExpress (MCE) Product Catalog:

14

Inhibitors & Agonists

2

Peptides

2

Inhibitory Antibodies

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-126378

    Kallikrein Inflammation/Immunology
    LSP-249 (example 35), extracted from patent WO2016011209A1, is a plasma kallikrein inhibitor under the study for angioedema, with an EC50 less than 100 nM in cell .
    LSP-249
  • HY-16735
    Avoralstat
    4 Publications Verification

    BCX4161

    Kallikrein Others
    Avoralstat (BCX4161), a potent and orally active plasma kallikrein (PKK) inhibitor, is used for hereditary angioedema research .
    Avoralstat
  • HY-108814A

    DX-88 TFA

    Kallikrein Cardiovascular Disease
    Ecallantide (DX-88) TFA is a specific recombinant plasma kallikrein inhibitor. Ecallantide inhibits the production of bradykinin. Ecallantide may be used to prevent acute attacks of angioedema .
    Ecallantide TFA
  • HY-P99631
    Garadacimab
    1 Publications Verification

    CSL312

    Factor Xa Cardiovascular Disease
    Garadacimab (CSL312) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research .
    Garadacimab
  • HY-P99110

    SHP643; DX-2930

    Kallikrein Inflammation/Immunology
    Lanadelumab (SHP643) is a human IgG1 monoclonal antibody against plasma kallikrein (pKal) with an Ki value of 0.12 nM. Lanadelumab inhibits both free and HMWK (high molecular weight kininogen)-bound pKal. Lanadelumab has the potential for the research of hereditary angioedema .
    Lanadelumab
  • HY-109127
    Berotralstat
    1 Publications Verification

    BCX7353

    Kallikrein Cancer
    Berotralstat (BCX7353) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema .
    Berotralstat
  • HY-108814

    DX-88

    Kallikrein Cardiovascular Disease
    Ecallantide (DX-88) is a specific plasma kallikrein inhibitor. Ecallantide inhibits the production of bradykinin. Ecallantide can be used to prevent acute attacks of angioedema .
    Ecallantide
  • HY-163464

    Kallikrein Cardiovascular Disease
    Plasma kallikrein-IN-5 (Compound 20) is a potent covalent inhibitor of plasma potassium kinin peptide (Pka) with IC50 values of 66 nM and 70 pM at 1 minute and 24 hours, respectively. Plasma kallikrein-IN-5 can be used IN the study of hereditary angioedema (HAE) .
    Plasma kallikrein-IN-5
  • HY-143476

    Kallikrein Cardiovascular Disease Metabolic Disease
    Plasma kallikrein-IN-2 (Compound 198) is a potent plasma kallikrein (PKal) inhibitor with an IC50 of 0.1 nM. Plasma kallikrein-IN-2 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research .
    Plasma kallikrein-IN-2
  • HY-150052

    Kallikrein Cardiovascular Disease Metabolic Disease
    Plasma kallikrein-IN-3 is a plasma kallikrein inhibitor (IC50: 0.15 μM). Plasma kallikrein-IN-3 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research .
    Plasma kallikrein-IN-3
  • HY-114412

    Angiotensin Receptor Neprilysin Inflammation/Immunology Endocrinology
    TD-0212 (compound 35) is an orally active dual pharmacology angiotensin II type 1 receptor (AT1) antagonist and neprilysin (NEP) inhibitor, with a pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP .
    TD-0212
  • HY-114412A

    Angiotensin Receptor Neprilysin Inflammation/Immunology
    TD-0212 TFA is an orally active dual pharmacology angiotensin II type 1 receptor (AT1) antagonist and neprilysin (NEP) inhibitor, with a pKi of 8.9 for AT1 and a pIC50 of 9.2 for NEP .
    TD-0212 TFA
  • HY-109127A
    Berotralstat dihydrochloride
    1 Publications Verification

    BCX7353 dihydrochloride

    Kallikrein Others
    Berotralstat dihydrochloride is a low toxicity, effective, highly specific, second-generation, synthetic and orally active plasma kallikrein inhibitor used for the research of hereditary angioedema (HAE) attacks. Berotralstat dihydrochloride works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE .
    Berotralstat dihydrochloride
  • HY-109127R

    Ser/Thr Protease Others
    Berotralstat (Standard) is the analytical standard of Berotralstat. This product is intended for research and analytical applications. Berotralstat (BCX7353) is a low toxicity, effective, highly specific, second-generation, synthetic and orally active plasma kallikrein inhibitor used for the research of hereditary angioedema (HAE) attacks. Berotralstat works by blocking the enzymatic activity of plasma kallikrein in releasing bradykinin, the major biologic peptide that promotes swelling and pain associated with attacks of HAE .
    Berotralstat (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: